We are live on
!
Find out more
AA
AlphaCentric Advisors Portfolio holdings
AUM
$100M
This Fund
S&P 500
This Quarter
Est. Return
-2.91%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$136M
AUM Growth
-$30M
(-18%)
Cap. Flow
-$21.6M
Cap. Flow
% of AUM
-15.92%
Top 10 Holdings %
Top 10 Hldgs %
25.49%
Holding
262
New
34
Increased
55
Reduced
87
Closed
45
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Enovis
ENOV
|
+$1.04M |
| 2 |
Amphastar Pharmaceuticals
AMPH
|
+$1.04M |
| 3 |
Invesco QQQ Trust
QQQ
|
+$958K |
| 4 |
Invesco NASDAQ 100 ETF
QQQM
|
+$955K |
| 5 |
Sarepta Therapeutics
SRPT
|
+$929K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UroGen Pharma
URGN
|
+$2.16M |
| 2 |
Corcept Therapeutics
CORT
|
+$2.14M |
| 3 |
NARI
Inari Medical, Inc. Common Stock
NARI
|
+$2.13M |
| 4 |
KALV
KalVista Pharmaceuticals
KALV
|
+$1.49M |
| 5 |
Perspective Therapeutics
CATX
|
+$1.35M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 60.25% |
| 2 | Real Estate | 12.98% |
| 3 | Financials | 6.42% |
| 4 | Industrials | 2.59% |
| 5 | Technology | 2.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Invesco NASDAQ 100 ETF
QQQM
$96.3B
| $1.56M | 1.15% |
7,899
+5,159
| +188% | +$955K |
|
|
DVAX
27
DELISTED
Dynavax Technologies
DVAX
| $1.46M | 1.08% |
130,000
+7,500
| +6% | +$87.3K |
|
|
MITT
28
TPG Mortgage Investment Trust
MITT
$243M
| $1.39M | 1.02% |
208,879
| – | – |
|
29
Medtronic
MDT
$106B
| $1.38M | 1.01% |
17,500
-3,000
| -15% | -$246K |
|
|
ITCI
30
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $1.37M | 1.01% |
20,000
| – | – |
|
31
BioMarin Pharmaceuticals
BMRN
$11.5B
| $1.36M | 1% |
16,500
+1,000
| +6% | +$83.3K |
|
32
GSK
GSK
$104B
| $1.35M | 0.99% |
35,000
| – | – |
|
33
Equity Lifestyle Properties
ELS
$12.8B
| $1.34M | 0.99% |
20,611
| – | – |
|
34
Enact Holdings
ACT
$6.49B
| $1.3M | 0.96% |
42,367
| – | – |
|
|
EXAS
35
DELISTED
Exact Sciences
EXAS
| $1.27M | 0.93% |
30,000
+1,000
| +3% | +$55K |
|
|
BCYC
36
Bicycle Therapeutics
BCYC
$294M
| $1.21M | 0.89% |
60,000
| – | – |
|
37
Axsome Therapeutics
AXSM
$11.8B
| $1.21M | 0.89% |
15,000
-17,500
| -54% | -$1.3M |
|
38
Synopsys
SNPS
$73.6B
| $1.19M | 0.88% |
2,000
-500
| -20% | -$283K |
|
|
39
Sarepta Therapeutics
SRPT
$1.82B
| $1.19M | 0.87% |
7,500
+7,231
| +2,688% | +$929K |
|
40
Jazz Pharmaceuticals
JAZZ
$15.5B
| $1.17M | 0.86% |
11,000
+2,500
| +29% | +$275K |
|
|
ADAM
41
Adamas Trust
ADAM
$807M
| $1.17M | 0.86% |
200,963
| – | – |
|
42
Stereotaxis
STXS
$154M
| $1.09M | 0.8% |
600,000
| – | – |
|
43
Structure Therapeutics
GPCR
$3.45B
| $1.02M | 0.75% |
26,000
-1,500
| -5% | -$61.6K |
|
|
44
Amphastar Pharmaceuticals
AMPH
$871M
| $1M | 0.74% |
+25,000
| New | +$1.04M |
|
45
Karyopharm Therapeutics
KPTI
$216M
| $976K | 0.72% |
75,000
| – | – |
|
|
TRML
46
DELISTED
Tourmaline Bio
TRML
| $965K | 0.71% |
75,000
+13,900
| +23% | +$224K |
|
47
Neurocrine Biosciences
NBIX
$17.2B
| $964K | 0.71% |
7,000
| – | – |
|
48
Immunovant
IMVT
$8.27B
| $964K | 0.71% |
36,500
-1,500
| -4% | -$42.7K |
|
49
Roivant Sciences
ROIV
$24.8B
| $930K | 0.68% |
88,000
-2,000
| -2% | -$21.9K |
|
|
50
Enovis
ENOV
$1.56B
| $904K | 0.67% |
+20,000
| New | +$1.04M |
|
Similar funds
WCM
FCM
BIA
AGAM
E
HCM
AC
OIS
AlphaCentric Advisors's Q2 2024 Portfolio in Review
As of Q2 2024, AlphaCentric Advisors held 262 positions worth $136M, down 18% from $166M the previous quarter. Its ten largest holdings account for 25% of the portfolio.
AlphaCentric Advisors withdrew a net $21.6M in Q2 2024, closing 45 positions and reducing 87 holdings. Its most notable exit was UroGen Pharma, an estimated $2.16M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 60% of assets, down from 61% a quarter earlier, followed by Real Estate and Financials.
Against the trend, AlphaCentric Advisors opened a new position in Enovis worth $904K.
- AlphaCentric Advisors's largest Q2 2024 buy was Enovis: 20,000 shares worth $904K.
- AlphaCentric Advisors added most to Invesco QQQ Trust in Q2 2024, an estimated $958K increase.
- AlphaCentric Advisors's biggest Q2 2024 reduction was Inari Medical, Inc. Common Stock, cutting an estimated $2.13M.
- AlphaCentric Advisors fully exited UroGen Pharma in Q2 2024, selling an estimated $2.16M.
- AlphaCentric Advisors's ten largest holdings make up 25% of its $136M portfolio in Q2 2024.
- AlphaCentric Advisors opened 34 new positions and closed 45 in Q2 2024.
- AlphaCentric Advisors's portfolio value fell 18% quarter-over-quarter to $136M.
Based on AlphaCentric Advisors's 13F filing for Q2 2024, filed 25 Jul 2024.